(R)-N-(Pyrrolidin-3-yl)pyrimidin-2-amine dihydrochloride, 1g

TASQUINIMOD, 95%, 50mg

2-(Benzo[d]thiazol-2-ylthio)succinic acid, 95.0%, 5g

2,3-Dibromo-5-methylpyridine, 98.0%, 5g

Bismuth(III) oxide, min. 99.5%, pa, 10 g, plastic packaging.

2-methyl-1H-benzimidazol-6-amine dihydrochloride, 95.0%, 10g

ethyl 4-(3,5-dimethoxyphenyl)-4-oxobutyrate, 97.0%, 2g

DOTA-tris(tBu)ester NHS ester, 250mg

2-(2-(Difluoromethoxy)phenyl)-2-hydroxyacetic acid, 98%, 250mg

2-Bromo-5-(trifluoromethoxy)benzaldehyde, 95.0%, 250mg

7-amino-1,3-dimethyl-5-(2-methylphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile, 1g

1,2-Bis(4-pyridylcarbonyl)hydrazine, 97%, 250mg

5-Bromoisophthalaldehyde, 95.0%, 25g